These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 38979627)

  • 1. Construction of Hierarchically Biomimetic Iron Oxide Nanosystems for Macrophage Repolarization-Promoted Immune Checkpoint Blockade of Cancer Immunotherapy.
    Kang Y; Yan J; Han X; Wang X; Wang Y; Song P; Su X; Rauf A; Jin X; Pu F; Zhang H
    ACS Appl Mater Interfaces; 2024 Jul; 16(28):36131-36141. PubMed ID: 38979627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hybrid Cellular Nanovesicles Block PD-L1 Signal and Repolarize M2 Macrophages for Cancer Immunotherapy.
    Zhao C; Pan Y; Liu L; Zhang J; Wu X; Liu Y; Zhao XZ; Rao L
    Small; 2024 Aug; 20(31):e2311702. PubMed ID: 38456371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Decorated Nanoplatform to Reprogram Macrophage and Block Immune Checkpoint LSECtin for Effective Cancer Immunotherapy.
    Xu R; Liu X; Zhang Y; Wu G; Huang L; Li R; Xu X
    Nano Lett; 2024 Jul; 24(28):8723-8731. PubMed ID: 38968148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fe
    Sun H; Wang X; Guo Z; Hu Z; Yin Y; Duan S; Jia W; Lu W; Hu J
    Int J Nanomedicine; 2024; 19():7185-7200. PubMed ID: 39050876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomimetic Iron-Based Nanoparticles Remodel Immunosuppressive Tumor Microenvironment for Metabolic Immunotherapy.
    Zhang W; Li L; Wu Y; Li C; Xu Z; Zhang N; Wang X; Zhao Y; Zu T; He Q; Jiao J; Zheng R
    Int J Nanomedicine; 2024; 19():9333-9349. PubMed ID: 39286354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
    Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
    Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
    J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery.
    Zhang X; Yue L; Cao L; Liu K; Yang S; Liang S; Liu L; Zhao C; Wu D; Wang Z; Tian R; Rao L
    Acta Biomater; 2024 Sep; 186():369-382. PubMed ID: 39097127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism/Immunity Dual-Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate-Excretion Inhibition and PD-1/PD-L1 Blockade.
    Li T; Xu D; Ruan Z; Zhou J; Sun W; Rao B; Xu H
    Adv Sci (Weinh); 2024 May; 11(18):e2310163. PubMed ID: 38460167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M1 Macrophage-Derived Nanovesicles Potentiate the Anticancer Efficacy of Immune Checkpoint Inhibitors.
    Choo YW; Kang M; Kim HY; Han J; Kang S; Lee JR; Jeong GJ; Kwon SP; Song SY; Go S; Jung M; Hong J; Kim BS
    ACS Nano; 2018 Sep; 12(9):8977-8993. PubMed ID: 30133260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy.
    Jin S; Wang H; Li Y; Yang J; Li B; Shi P; Zhang X; Zhou X; Zhou X; Niu X; Wu M; Wu Y; Zhai W; Qi Y; Gao Y; Zhao W
    Cell Commun Signal; 2024 Mar; 22(1):173. PubMed ID: 38462636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulation of Tumor Microenvironment by Arginine-Loaded Iron Oxide Nanoparticles for Gaseous Immunotherapy.
    Wu X; Cheng Y; Zheng R; Xu K; Yan J; Song P; Wang Y; Rauf A; Pan Y; Zhang H
    ACS Appl Mater Interfaces; 2021 May; 13(17):19825-19835. PubMed ID: 33881837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice.
    Tsuruta A; Shiiba Y; Matsunaga N; Fujimoto M; Yoshida Y; Koyanagi S; Ohdo S
    Mol Cancer Res; 2022 Jun; 20(6):972-982. PubMed ID: 35190830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 15. Engineering nanoparticles-enabled tumor-associated macrophages repolarization and phagocytosis restoration for enhanced cancer immunotherapy.
    Gong Y; Gao W; Zhang J; Dong X; Zhu D; Ma G
    J Nanobiotechnology; 2024 Jun; 22(1):341. PubMed ID: 38890636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
    Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.